Publications by authors named "Emmanuelle Massie"
Article Synopsis
- Desmoplakin cardiomyopathy is a recently defined heart condition causing left ventricular dysfunction, often leading to inflammation, fibrosis, and arrhythmias.
- A case study highlights a 46-year-old woman with this condition, who experienced multiple cardiac arrests due to a new variant in the desmoplakin gene and showed little improvement after receiving immunosuppressive treatment.
- The condition should be included in the evaluation of inflammatory heart diseases, and while some patients may benefit from immunosuppressive therapy, its effectiveness remains largely unknown.
Combined lactic acidosis and ketoacidosis in a female diabetic patient with severe heart failure.
Cardiovasc Endocrinol Metab
September 2023
SGLT2i are now recommended in a wide spectrum of indications including type 2 diabetes (T2DM), heart failure, and chronic kidney disease. This medication class is now available in combination with metformin, which is still a fundamental treatment in patients with T2DM. Despite excellent proven safety profile for both drugs, the expanding use of these agents in clinical practice may lead to an increased incidence of rare side effects, like metformin-associated lactic acidosis (MALA) and euglycemic diabetic ketoacidosis (EDKA), which can be life-threatening.
View Article and Find Full Text PDFPrimary pulmonary artery sarcoma is an exceedingly rare and aggressive malignancy that carries poor prognosis. Clinical manifestations are nonspecific and include chest pain, dyspnea, syncope, palpitations, and asthenia, among others. Delay to diagnosis is common and compromises the prognosis.
View Article and Find Full Text PDFThe patient cohort with left ventricular ejection fractions (LVEFs) of 41%-49%, which has been defined as heart failure with midrange ejection fraction (HFmrEF), represent a significant proportion of the heart failure (HF) population. Despite the clear cutoffs established by different society guidelines, confusion remains regarding the exact significance of midrange LVEF within the HF syndrome. Patients with LVEF 41%-49% represent a heterogeneous group of patients sharing pathophysiologic mechanisms, biomarker profiles, comorbidities, and clinical characteristics with patients with preserved and reduced LVEF.
View Article and Find Full Text PDFPurpose Of Review: While use of implantable cardioverter defibrillator (ICD) in patients with heart failure (HF) and reduced ejection fraction is recommended, their role in patients with left ventricular assist device (LVAD) remains controversial, especially with continuous flow (CF) devices.
Recent Findings: Ventricular arrhythmias (VA) in LVAD patients are frequent and associated with worse outcomes, especially postoperatively. Data on the role of ICDs in LVAD patients are scarce, based on case reports or small retrospective series.